Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the...
07 Octobre 2020 - 10:20PM
Today, Jennifer Doudna, Ph.D., one of Intellia Therapeutics, Inc.’s
scientific co-founders, was awarded the 2020 Nobel Prize in
Chemistry for the development of the CRISPR/Cas9 genome editing
technology. Dr. Doudna shared the award with her research
collaborator, Dr. Emmanuelle Charpentier. This is the first time
two women scientists have jointly won a Nobel Prize in Chemistry.
Since the publication of the seminal 2012 Science paper, Dr.
Doudna has been widely recognized by the global scientific
community for her pioneering invention and many contributions to
CRISPR/Cas9 technology. This paper showed for the first time the
necessary and essential components for the CRISPR/Cas9 system and
how it could be used as a versatile genome editing tool in any
non-cellular and cellular setting. Acting as a pair of programmable
molecular scissors, the CRISPR/Cas9 system uses sequence-specific
RNA guides to recognize DNA targets and activate a protein known as
Cas9 to cut the DNA. This activity is fundamental to editing DNA,
and it serves as the genetic basis for a vast array of potential
applications. For their CRISPR/Cas9 invention, Drs. Doudna and
Charpentier have been awarded the Lurie Prize in the Biomedical
Sciences, the Dr. Paul Janssen Award for Biomedical Research, the
Dr. H. P. Heineken Prize for Biochemistry and Biophysics, and the
LUI Che Woo Prize for Welfare Betterment, among other
recognitions.
“We congratulate Dr. Doudna and Dr. Charpentier on winning the
2020 Nobel Prize in Chemistry for their revolutionary invention of
CRISPR/Cas9,” said Intellia President and Chief Executive Officer
John Leonard, M.D. “Their CRISPR/Cas9 invention is already being
applied in ways that are transforming science and medicine. Our
team at Intellia is honored to be using this powerful tool in our
work to develop potential cures for people suffering from
conditions ranging from genetic disease to cancer. We are proud of
Dr. Doudna and our other scientific co-founders, Drs. Rodolphe
Barrangou, Eric Sontheimer, Luciano Marrafini and Derrick Rossi,
who have each made, and continue to make, tremendous contributions
to the genomics field.”
About Jennifer DoudnaDr. Doudna is a faculty
member of the Molecular and Cell Biology and Chemistry department
at UC Berkeley, where she is the Li Ka Shing Chancellor’s Professor
of Biomedical Science, as well as a Howard Hughes Medical Institute
investigator, and a faculty scientist at the Lawrence Berkeley
National Laboratory. Dr. Doudna also is a senior investigator at
the Gladstone Institutes and an adjunct professor of Cellular and
Molecular Pharmacology at UC San Francisco. She was elected as
a fellow of the National Academy of Sciences in 2002 and the
American Academy of Arts and Sciences in 2003.
About CRISPR/Cas9 Genome Editing
Treatments Genome editing is efficient, precise and
scalable. CRISPR/Cas9 genome editing can make permanent, precisely
targeted changes in patients’ chromosomes and repair the underlying
genetic mutation, whereas more traditional gene therapy typically
involves introducing a non-permanent copy of a gene into patients’
cells. These attributes of CRISPR/Cas9 provide a significant
therapeutic edge over other gene therapy and costly
earlier-generation genome editing technologies, such as zinc finger
nucleases and transcription activator-like effector nucleases.
Intellia’s proprietary CRISPR/Cas9 system could potentially
address diseases with a single course of treatment because it
permanently repairs the defective DNA. This represents a
breakthrough improvement over current therapies, most of which
require lifelong administration because they cannot correct
underlying causes of the disease.
About Intellia TherapeuticsIntellia
Therapeutics is a leading genome editing company, focused on
the development of proprietary, potentially curative therapeutics
using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9
technology has the potential to transform medicine by producing
single-course therapeutics that permanently edit and correct
disease-associated genes, and creating enhanced engineered cells
that can treat oncological and immunological diseases. Intellia’s
combination of deep scientific, technical and clinical development
experience, along with its leading intellectual property portfolio,
puts it in a unique position to unlock broad therapeutic
applications of the CRISPR/Cas9 technology and create new classes
of therapeutic products. Learn more about Intellia
Therapeutics and CRISPR/Cas9 at intelliatx.com. Follow us
on Twitter @intelliatweets.
Forward-Looking Statements
This press release contains “forward-looking statements”
of Intellia Therapeutics, Inc. (“Intellia”) within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, but are not limited to,
express or implied statements regarding Intellia’s ability to
advance and expand the CRISPR/Cas9 technology to develop into human
therapeutic products, as well as our CRISPR/Cas9 intellectual
property portfolio; achieve stable or effective genome editing; the
timing and potential achievement of milestones to advance our
pipeline and grow as a company; and the anticipated contribution of
the members of our board of directors and our executives, or our
scientific founders, to our operations and progress.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs of future events,
and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those
set forth in or implied by such forward-looking statements. These
risks and uncertainties include, but are not limited to: risks
related to Intellia’s ability to protect and maintain its
intellectual property position; risks related to Intellia’s
relationship with third parties, including its licensors and
licensees; risks related to the ability of its licensors to protect
and maintain their intellectual property position; uncertainties
related to the authorization, initiation and conduct of studies and
other development requirements for its product candidates; the risk
that any one or more of Intellia’s CRISPR/Cas9 product candidates
will not be successfully developed and commercialized; and the risk
that the results of preclinical studies or clinical studies will
not be predictive of future results in connection with future
studies. For a discussion of these and other risks and
uncertainties, and other important factors, any of which could
cause Intellia’s actual results to differ from those contained in
the forward-looking statements, see the section entitled “Risk
Factors” in Intellia’s most recent annual report on Form 10-K as
well as discussions of potential risks, uncertainties, and other
important factors in Intellia’s other filings with
the Securities and Exchange Commission. All information in
this press release is as of the date of the release, and Intellia
undertakes no duty to update this information unless required by
law.
Intellia Contacts:
Media:Jennifer Mound SmoterSenior Vice
President
External Affairs &
Communications
+1 857-706-1071
jenn.smoter@intelliatx.com
Lynnea OlivarezDirectorExternal Affairs & Communications+1
956-330-1917lynnea.olivarez@intelliatx.com
Investors:Lina LiAssociate DirectorInvestor
Relations+1 857-706-1612lina.li@intelliatx.com
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Intellia Therapeutics (NASDAQ:NTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024